Bildkälla: Stockfoto

Xspray Pharma: Resubmission Q1 2025 - Redeye

Redeye provides a comment on Xspray following yesterday's press release announcing a delay in the resubmission of its NDA to March/April 2025, compared to the previous timeline of Q4 2024. We adjust our valuation accordingly.

Redeye provides a comment on Xspray following yesterday's press release announcing a delay in the resubmission of its NDA to March/April 2025, compared to the previous timeline of Q4 2024. We adjust our valuation accordingly.
Börsvärldens nyhetsbrev
ANNONSER